Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Major Amendment To Oral Testosterone NDA Extends FDA Review

By Lipocine Inc. | November 20, 2017

U.S. FDA extends review for Tlando; advisory committee meeting date of January 10, 2018 remains unchanged.

Lipocine Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for Tlando, the company’s oral testosterone product candidate for the proposed indication of testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. 

The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) goal date of May 8, 2018.

The FDA extended the action goal date to allow time to review additional data analyses recently submitted as an amendment to the NDA in response to the FDA’s information requests. Upon preliminary review of the amendment by the FDA, the submission of the requested information has been determined to represent a ‘major amendment’ to the NDA resulting in an extension of the PDUFA goal date by three months to provide time for a full review.

The previously scheduled Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) meeting on January 10, 2018 to discuss the NDA for Tlando remains unchanged.

“We believe Tlando addresses a significant unmet medical need for men with hypogonadism and we will continue to work closely with the FDA throughout the review process,” said Dr. Mahesh Patel, chairman, president and chief executive officer of Lipocine.

(Source: Lipocine Inc.)


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE